About: Proceedings from the 2(nd) Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Proceedings from the 2(nd) Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Proceedings from the 2(nd) Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019
Creator	Schulert, Grant Debenedetti, Fabrizio Canna, Scott Gadina, Massimo Grom, Alexei Boutelle, Jonathan Brunner, Hermine De Jesus, Adriana Goldbach-Mansky, Raphaela Levine, Stewart Pickering, Alex Sinha, Rashmi
Source	PMC
abstract	For reasons poorly understood, and despite the availability of biological medications blocking IL-1 and IL-6 that have markedly improved overall disease control, children with Systemic Juvenile Idiopathic Arthritis (SJIA) are now increasingly diagnosed with life-threatening chronic complications, including hepatitis and lung disease (SJIA-LD). On October 3–4, 2019, a two-day meeting, NextGen Therapies for Systemic Juvenile Idiopathic Arthritis (SJIA) & macrophage activation syndrome (MAS) organized by the Systemic JIA Foundation (www.systemicjia.org/) in Washington, DC brought together scientists, clinicians, parents and FDA representatives with the objectives (1) to integrate clinical and research findings in MAS and SJIA-LD, and (2) to develop a shared understanding of this seemingly new pulmonary complication of SJIA. The current manuscript summarizes discussions and conclusions of the meeting.
has issue date	2020-07-15(xsd:dateTime)
bibo:doi	10.1186/s12969-020-00444-7
has license	cc-by
sha1sum (hex)	df4f95264864730bb3246d75eb6445c15572d4b6
schema:url	https://doi.org/10.1186/s12969-020-00444-7
resource representing a document's title	Proceedings from the 2(nd) Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019
has PubMed Central identifier	PMC7360380
schema:publication	Pediatr Rheumatol Online J
resource representing a document's body	covid:df4f95264864730bb3246d75eb6445c15572d4b6#body_text
is schema:about of	named entity 'Juvenile Idiopathic Arthritis' named entity 'Systemic' named entity 'IL-1' named entity 'CONCLUSIONS' named entity 'DISCUSSIONS' named entity 'DISEASE CONTROL' named entity 'TO INTEGRATE' named entity 'LIFE' named entity 'Foundation' named entity 'develop' named entity 'complication' named entity 'summarizes' named entity 'disease' named entity '2019' named entity 'manuscript' named entity 'SJIA' named entity 'Systemic Juvenile Idiopathic Arthritis' named entity 'MAS' named entity 'Systemic Juvenile Idiopathic Arthritis' named entity 'Systemic Juvenile Idiopathic Arthritis' named entity 'histopathologic features' named entity 'alveolar' named entity 'Europe' named entity 'methotrexate' named entity 'innate immune' named entity 'MAS' named entity 'cytokines' named entity 'NLRC4' named entity 'speech therapy' named entity 'lipids' named entity 'gene expression profile' named entity 'Systemic Juvenile Idiopathic Arthritis' named entity 'Novartis' named entity 'lung lavage' named entity 'steroids' named entity 'Systemic Juvenile Idiopathic Arthritis' named entity 'rash' named entity 'MAS' named entity 'pneumonia' named entity 'combination therapy' named entity 'immune responses' named entity 'PRO' named entity 'lung inflammation' named entity 'liver abnormalities' named entity 'CD4' named entity 'tachypnea' named entity 'canakinumab' named entity 'cytokine' named entity 'productive cough' named entity 'tocilizumab' named entity 'MAS' named entity 'viral infection' named entity 'HRCT' named entity 'fatigue' named entity 'LDH' named entity 'immunosuppression' named entity 'interferon' named entity 'Systemic Juvenile Idiopathic Arthritis' named entity 'Systemic Juvenile Idiopathic Arthritis' named entity 'Systemic Juvenile Idiopathic Arthritis' named entity 'canakinumab' named entity 'lipid' named entity 'infusion' named entity 'ferritin' named entity 'homeostasis' named entity 'Systemic Juvenile Idiopathic Arthritis' named entity 'azathioprine' named entity 'MAS' named entity 'therapeutic strategies' named entity 'Kupffer cells' named entity 'MAS' named entity 'SJIA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software